Case Study
Year: 2022 | Month: October-December | Volume: 7 | Issue: 4 | Pages: 260-262
DOI: https://doi.org/10.52403/ijshr.20221036
A Case Study Showing Benralizumab’s Effectiveness in Treating Uncontrolled Severe Eosinophilic Asthma That is Resistant to Omalizumab
Dr. Stelphy Stephen
Department of Pharmacy Practice, C.L Baid Metha College of Pharmacy, Tamil Nadu Dr. MGR Medical University, Chennai, Tamil Nadu, India - 600097
ABSTRACT
Asthma is a diverse illness that can range in severity. Because it has a significant impact on patients' quality of life and because people with severe asthma have symptoms, exacerbations, and drug side effects. Although first disregarded, eosinophils have since been directly linked to characteristics of the continuous inflammatory process in asthma, especially in the severe form. We present of the case of a 50year old female patient who presented with complaints of cough, breathing difficult on exertion and history of fever, chest pain and tiredness. The chest x ray showed left lower zone haziness. Patient was successfully treated with IV antibiotics, IV Proton pump inhibitor, Nebulised bronchodilators, IV Steroids, Anti-Hypertensive therapy and all other supportive medications along with pulmonary rehabilitations. In view of uncontrolled Eosinophilic asthma patient was treated with monoclonal antibody. Patient improved symptomatically better. This case study describes how benralizumab treatment for a patient with uncontrolled severe eosinophilic asthma resulted in significant improvements in lung function, asthma control, steroid use, and quality of life.
Keywords: Benralizumab, Severe eosinophilic asthma, Omalizumab, Monoclonal antibodiesXYZ